Business News • PR NewsWire • European Hematology Association - Pegcetacoplan Maintains a Durable Response in Patients with Paroxysmal Nocturnal Hemoglobinuria Through Week 48

European Hematology Association - Pegcetacoplan Maintains a Durable Response in Patients with Paroxysmal Nocturnal Hemoglobinuria Through Week 48

European Hematology Association - Pegcetacoplan Maintains a Durable Response in Patients with Paroxysmal Nocturnal Hemoglobinuria Through Week 48

THE HAGUE, Netherlands, June 12, 2021 /PRNewswire/ -- The PEGASUS phase-3 study previously demonstrated that pegcetacoplan, a drug controlling intra- and extravascular hemolysis, was superior to eculizumab in patients with paroxysmal nocturnal hemoglobinuria at the week 16 endpoint of the...

View More : https://www.prnewswire.com:443/news-releases/european-hematology-association---pegcetacoplan-maintains-a-durable-respons...

Releted News by prnewswire

Risen Energy Unveils NewT@N at SNEC 2021, the Industry's First Mass-Produced 700W High-Efficiency Power Module

Long-lasting Chlorine Dioxide (ClO2) Aqueous Solution Presented by Taiko Pharmaceutical and Kitasato University Inactivates over 99.99% of SARS-CoV-2 (COVID-19 Virus)

European Hematology Association: Humoral Response to the Pfizer/BioNTech BNT162b2 Vaccine Is Impaired in Patients Receiving CAR-T or High-Intensity Immunosuppressive Therapy

European Hematology Association - Pegcetacoplan Maintains a Durable Response in Patients with Paroxysmal Nocturnal Hemoglobinuria Through Week 48

European Hematology Association- First-Line Ibrutinib + Venetoclax Is Superior to Chlorambucil + Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocyte Lymphoma

USD 0.66 Billion growth expected in Health Economics Outcomes Research Services Market| SpendEdge

Прогресс Shanghai Electric в строительстве башни CSP и параболоцилиндрической установки